{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T01:48:43Z","timestamp":1784166523531,"version":"3.55.0"},"reference-count":60,"publisher":"Wiley","license":[{"start":{"date-parts":[[2022,10,7]],"date-time":"2022-10-07T00:00:00Z","timestamp":1665100800000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"37 Military Hospital"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Disease Markers"],"published-print":{"date-parts":[[2022,10,7]]},"abstract":"<jats:p>Introduction. Prostate cancer is one of the most commonly diagnosed cancers in men. Prostate-specific antigen (PSA) has been the biomarker of choice for screening and diagnosis of prostate cancer. However, inefficiencies exist with its diagnostic capabilities. This study thus evaluated the diagnostic and prognostic potential of urinary PCA3 as an alternative biomarker for prostate cancer in the Ghanaian population. Methods. A hospital-based cross-sectional study was conducted at the Urology Department of the 37 Military Hospital, Accra, Ghana. A total of 237 participants aged 40 years and above with any form of suspected prostate disorder were recruited into the study after written informed consent was obtained. Total serum PSA levels was measured using the electrochemiluminescence method and transrectal ultrasound-guided systematic core needle biopsies were obtained from each study participant. Receiver operating characteristic curve (ROC) analysis was used to evaluate the diagnostic accuracies of serum PSA, DRE, and PCA3 as diagnostic tools for prostate cancer. These three diagnostic tools were also evaluated in various combinations to ascertain the combinations with the best diagnostic accuracy. Results. Prostate cancer was diagnosed in 26.6% of the participants. Benign prostate hyperplasia and prostatitis were diagnosed in 48.5% and 24.9% participants, respectively. DRE had a sensitivity of 93.7% and a specificity of 12.1%. PSA had a sensitivity of 92.1% and a specificity of 16.1%. PCA3 had a sensitivity of 57.1% and a specificity of 85.6% and showed a better accuracy (<jats:inline-formula>\n                     <a:math xmlns:a=\"http:\/\/www.w3.org\/1998\/Math\/MathML\" id=\"M1\">\n                        <a:mtext>AUC<\/a:mtext>\n                        <a:mo>=<\/a:mo>\n                        <a:mn>83.0<\/a:mn>\n                     <\/a:math>\n                  <\/jats:inline-formula>) compared to PSA (<jats:inline-formula>\n                     <c:math xmlns:c=\"http:\/\/www.w3.org\/1998\/Math\/MathML\" id=\"M2\">\n                        <c:mtext>AUC<\/c:mtext>\n                        <c:mo>=<\/c:mo>\n                        <c:mn>60.0<\/c:mn>\n                     <\/c:math>\n                  <\/jats:inline-formula>) and DRE (<jats:inline-formula>\n                     <e:math xmlns:e=\"http:\/\/www.w3.org\/1998\/Math\/MathML\" id=\"M3\">\n                        <e:mtext>AUC<\/e:mtext>\n                        <e:mo>=<\/e:mo>\n                        <e:mn>65.0<\/e:mn>\n                     <\/e:math>\n                  <\/jats:inline-formula>) as individual diagnostic tools. The combination of DRE+PCA3 score had the best diagnostic accuracy (<jats:inline-formula>\n                     <g:math xmlns:g=\"http:\/\/www.w3.org\/1998\/Math\/MathML\" id=\"M4\">\n                        <g:mtext>AUC<\/g:mtext>\n                        <g:mo>=<\/g:mo>\n                        <g:mn>0.80<\/g:mn>\n                     <\/g:math>\n                  <\/jats:inline-formula>) with a sensitivity and specificity of 60.3% and 80.5%, respectively. Conclusion. The urinary PCA3 assay showed a better diagnostic performance compared to serum PSA and DRE. PCA3 as a stand-alone and in combination with DRE could be a suitable complimentary marker in diagnosis and management of prostate cancer.<\/jats:p>","DOI":"10.1155\/2022\/1686991","type":"journal-article","created":{"date-parts":[[2022,10,7]],"date-time":"2022-10-07T19:20:28Z","timestamp":1665170428000},"page":"1-10","source":"Crossref","is-referenced-by-count":17,"title":["Urinary PCA3 a Superior Diagnostic Biomarker for Prostate Cancer among Ghanaian Men"],"prefix":"10.1155","volume":"2022","author":[{"given":"Bismark","family":"Opoku Mensah","sequence":"first","affiliation":[{"name":"Department of Molecular Medicine, KSMD, KNUST, Ghana"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0252-3190","authenticated-orcid":true,"given":"Linda Ahenkorah","family":"Fondjo","sequence":"additional","affiliation":[{"name":"Department of Molecular Medicine, KSMD, KNUST, Ghana"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"W. K. B. A.","family":"Owiredu","sequence":"additional","affiliation":[{"name":"Department of Molecular Medicine, KSMD, KNUST, Ghana"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ben","family":"Adusei","sequence":"additional","affiliation":[{"name":"Urology Unit, 37 Military Hospital, Accra, Ghana"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","reference":[{"key":"1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0153496"},{"key":"2","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.25516"},{"key":"3","volume-title":"Cancer in Africa. IARC Scientific Publication No. 153.","author":"D. M. Parkin","year":"2003"},{"key":"4","doi-asserted-by":"publisher","DOI":"10.1023\/A:1008966225984"},{"key":"5","doi-asserted-by":"publisher","DOI":"10.1016\/j.afju.2017.09.004"},{"key":"6","doi-asserted-by":"publisher","DOI":"10.1016\/j.suc.2015.05.001"},{"key":"7","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM200105033441806"},{"key":"8","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.3003180"},{"key":"9","doi-asserted-by":"publisher","DOI":"10.1007\/s13402-016-0268-6"},{"issue":"23","key":"10","first-page":"5975","article-title":"DD3: a new prostate-specific gene, highly overexpressed in prostate cancer","volume":"59","author":"M. J. Bussemakers","year":"1999","journal-title":"Cancer Research"},{"issue":"1","key":"11","first-page":"5","article-title":"PCA3: a new tool to diagnose prostate cancer (PCa) and a guidance in biopsy decisions. Preliminary report of the UrOP study","volume":"82","author":"F. Galasso","year":"2010","journal-title":"Archivio Italiano di Urologia, Andrologia"},{"key":"12","doi-asserted-by":"publisher","DOI":"10.1007\/s13193-012-0142-6"},{"key":"13","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2407-14-362"},{"key":"14","doi-asserted-by":"publisher","DOI":"10.1016\/j.juro.2014.04.017"},{"issue":"3","key":"15","first-page":"228","article-title":"The risk factors of prostate cancer and its prevention: a literature review","volume":"48","author":"N. R. Perdana","year":"2016","journal-title":"Acta Medica Indonesiana"},{"key":"16","volume-title":"SEER cancer statistics review, 1975\u20132010","author":"N. N. Howlader","year":"2013"},{"key":"17","doi-asserted-by":"publisher","DOI":"10.1016\/j.urology.2017.04.015"},{"key":"18","article-title":"Transition zone PSA density improves the prostate cancer detection rate both in PSA 4.0\u201310.0 and 10.1\u201320.0 ng\/ml in Chinese men","volume-title":"Urologic Oncology: Seminars and Original Investigations","author":"P. Tang","year":"2013"},{"key":"19","doi-asserted-by":"publisher","DOI":"10.1016\/0951-8320(92)90102-Q"},{"key":"20","doi-asserted-by":"publisher","DOI":"10.3322\/CA.2007.0010"},{"issue":"3","key":"21","first-page":"175","article-title":"Prostate cancer specificity of PCA3 gene testing: examples from clinical practice","volume":"10","author":"L. S. Marks","year":"2008","journal-title":"Reviews in Urology"},{"key":"22","doi-asserted-by":"publisher","DOI":"10.12954\/PI.14054"},{"issue":"1","key":"23","first-page":"24","article-title":"The discriminative ability of percent free PSA in patients with PSA> 10 ng\/ml","volume":"9","author":"B. Wadie","year":"2003","journal-title":"African Journal of Urology"},{"key":"24","doi-asserted-by":"publisher","DOI":"10.4103\/njbcs.njbcs_39_16"},{"key":"25","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2010.10.024"},{"key":"26","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2010.11.044"},{"key":"27","doi-asserted-by":"publisher","DOI":"10.1097\/01.ede.0000101022.38330.7c"},{"key":"28","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2559.2011.04033.x"},{"key":"29","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2490-14-53"},{"key":"30","doi-asserted-by":"publisher","DOI":"10.1016\/j.urology.2006.12.014"},{"key":"31","doi-asserted-by":"publisher","DOI":"10.1159\/000314078"},{"key":"32","doi-asserted-by":"publisher","DOI":"10.1016\/j.urology.2009.03.046"},{"key":"33","doi-asserted-by":"publisher","DOI":"10.1016\/B978-0-12-800077-9.00066-9"},{"key":"34","doi-asserted-by":"publisher","DOI":"10.4103\/0970-1591.159606"},{"key":"35","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2020.7589"},{"key":"36","doi-asserted-by":"publisher","DOI":"10.1002\/nbm.3002"},{"key":"37","doi-asserted-by":"publisher","DOI":"10.1177\/1756287221997186"},{"key":"38","doi-asserted-by":"crossref","first-page":"e701","DOI":"10.1016\/j.juro.2016.02.509","article-title":"MP53-12 the role of prostate cancer antigen 3 (PCA3) test and multi-parametric prostatic magnetic resonance imaging (MPMRI) among patients with prior negative biopsy: correlation with radical prostatectomy pathology","volume":"195","author":"T. Alkasab","year":"2016","journal-title":"The Journal of Urology"},{"key":"39","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13092047"},{"key":"40","first-page":"1522","article-title":"PCA3 sensitivity and specificity for prostate cancer detection in patients with abnormal PSA and\/or suspicious digital rectal examination. First Latin American experience","volume-title":"Urologic Oncology: Seminars and Original Investigations","author":"C. G. Ramos","year":"2013"},{"key":"41","doi-asserted-by":"publisher","DOI":"10.1186\/s13046-015-0127-8"},{"issue":"2","key":"42","first-page":"96","article-title":"Prostate cancer gene 3 urine assay cutoff in diagnosis of prostate cancer: a validation study on an Italian patient population undergoing first and repeat biopsy","volume":"34","author":"E. Bollito","year":"2012","journal-title":"Analytical and Quantitative Cytology and Histology"},{"key":"43","doi-asserted-by":"publisher","DOI":"10.1016\/j.juro.2013.02.018"},{"key":"44","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2008.06.071"},{"key":"45","doi-asserted-by":"publisher","DOI":"10.1016\/S0302-2838(03)00201-X"},{"key":"46","doi-asserted-by":"publisher","DOI":"10.4103\/1008-682X.125390"},{"key":"47","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2010.09.030"},{"issue":"9","key":"48","first-page":"16606","article-title":"High PCA3 scores in urine correlate with poor-prognosis factors in prostate cancer patients","volume":"8","author":"W. Wei","year":"2015","journal-title":"International Journal of Clinical and Experimental Medicine"},{"key":"49","doi-asserted-by":"publisher","DOI":"10.1373\/clinchem.2005.063289"},{"issue":"12","key":"50","first-page":"7159","article-title":"Comparison of prostate cancer gene 3 score, prostate health index and percentage free prostate-specific antigen for differentiating histological inflammation from prostate cancer and other non-neoplastic alterations of the prostate at initial biopsy","volume":"34","author":"S. De Luca","year":"2014","journal-title":"Anticancer Research"},{"key":"51","doi-asserted-by":"publisher","DOI":"10.1001\/jama.1994.03510290050036"},{"key":"52","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19921101)70:9<2313::AID-CNCR2820700917>3.0.CO;2-T"},{"key":"53","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.23277"},{"key":"54","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajur.2018.11.007"},{"key":"55","doi-asserted-by":"publisher","DOI":"10.1155\/2014\/890697"},{"key":"56","doi-asserted-by":"publisher","DOI":"10.13187\/ejm.2014.5.124"},{"key":"57","doi-asserted-by":"publisher","DOI":"10.1111\/j.1442-2042.1995.tb00468.x"},{"key":"58","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-5347(17)35233-3"},{"key":"59","doi-asserted-by":"publisher","DOI":"10.21037\/qims.2019.12.16"},{"key":"60","doi-asserted-by":"publisher","DOI":"10.4103\/0301-4738.37595"}],"container-title":["Disease Markers"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/downloads.hindawi.com\/journals\/dm\/2022\/1686991.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/downloads.hindawi.com\/journals\/dm\/2022\/1686991.xml","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/downloads.hindawi.com\/journals\/dm\/2022\/1686991.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,7]],"date-time":"2022-10-07T19:20:52Z","timestamp":1665170452000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.hindawi.com\/journals\/dm\/2022\/1686991\/"}},"subtitle":[],"editor":[{"given":"Francesco","family":"Del Giudice","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2022,10,7]]},"references-count":60,"alternative-id":["1686991","1686991"],"URL":"https:\/\/doi.org\/10.1155\/2022\/1686991","relation":{},"ISSN":["1875-8630","0278-0240"],"issn-type":[{"value":"1875-8630","type":"electronic"},{"value":"0278-0240","type":"print"}],"subject":[],"published":{"date-parts":[[2022,10,7]]}}}